Profusa, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.4M
- Price
- $5.46
- % Change (Daily % change from the live per-ticker quote feed.)
- -27.87%
- Volume
- 647.7K
About
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.
Quick stats
Shares outstanding253.5K
Computed float6.0K
Float / shares2.4%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001859807
Websitehttps://profusa.com
AI Summary
AI-generated1/23
standardmixedoperations update
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Profusa executed a 4:1 reverse stock split effective August 18, 2026 and converted $4.57 million of debt into Series A Preferred Stock as part of ongoing restructuring.
Q2 financial results showed a net loss of $8.8 million with only $719,000 cash on hand, though stockholders' equity is expected to swing to $28.4 million positive by July 31 following the Option Agreement execution.
The company continues progressing toward the acquisition of G3 Vision Labs, a commercial-stage diagnostics company, with G3's 2024 and 2025 PCAOB-audited financials expected by mid-September.
Red flags
- reverse stock split executed to maintain Nasdaq listing
- Q2 net loss widened to $8.8M from $2.3M year-over-year
- cash on hand only $719K at June 30, 2026
- borrowed $650K for near-term working capital needs